



For more information:  
Marta Campos Martínez  
[mcampos@rovi.es](mailto:mcampos@rovi.es)  
Tel: +34 91 244 44 22

## **Additional information on the termination of the negotiations with Novavax for flu vaccine collaboration**

**Madrid – 8<sup>th</sup> February 2010** – With regards to the Regulatory Filing with number 120.420 and dated 8<sup>th</sup> February 2010, Laboratorios Farmacéuticos Rovi (ROVI) clarifies that, despite the termination of the negotiations for the joint collaboration with Novavax, it continues to maintain 1,094,891 Novavax stocks, acquired through an equity investment of 3,004,501.34 US dollars in Novavax, Inc. company (Nasdaq: NVAX). The Company is free to maintain or not these stocks and as of the date of the regulatory filing no decision related to the stocks has been taken.

The termination of the agreement with Novavax means that ROVI will not make any future investment related to the development of vaccines using the Novavax's virus-like-particle (VLP) technology and therefore the plans to develop a Phase III clinical trial with this technology have been cancelled.

ROVI has not any present and future commitment of payment to Novavax as consequence of the termination of this agreement.

Finally, the Company continues to progress with the Ministry of Health and the Regional Ministries for Innovation and Science of the Regional Government of Andalusia, which have been properly informed about this circumstance, on the project development for the research of new technologies and the production of flu vaccines, under the protocol of intentions signed on 10<sup>th</sup> June 2009 in which Novavax was not involved as signer.

## **About ROVI**

ROVI is a fully integrated, profitable Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 27 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, bemiparin. ROVI's research and development pipeline is focused primarily on addressing currently unmet medical needs by developing new LMWH-based products and expanding applications for its existing LMWH-based products. ROVI manufactures the active biological ingredient (bemiparin) for its principal proprietary product and product candidates and the injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. Additional information about ROVI is available on the company's website: [www.rovi.es](http://www.rovi.es)